Investment Rating - The investment rating for the company is "Buy" with initial coverage [1] Core Insights - The company reported stable revenue growth in Q3 2025, with a total revenue of 610 million yuan, representing a 2.6% increase year-on-year. The net profit attributable to shareholders was 90 million yuan, up 20.9% year-on-year [4][5] - The gross margin improved significantly in Q3 2025, reaching 29.1%, an increase of 8.3 percentage points compared to the previous year. The net profit margin for Q3 was 15.2%, up 6.5 percentage points year-on-year [6] - The company is a leading player in the domestic SMO industry, with expectations for further recovery in the innovative drug financing market by 2026. Revenue forecasts for 2025, 2026, and 2027 are 830 million, 950 million, and 1.03 billion yuan, respectively, with corresponding net profits of 120 million, 160 million, and 180 million yuan [7] Company Overview - The latest closing price of the company's stock is 56.80 yuan, with a total market capitalization of 4.5 billion yuan. The company has a total share capital of 79 million shares, with 75 million shares in circulation. The highest and lowest prices in the last 52 weeks were 56.80 yuan and 24.84 yuan, respectively [3]
普蕊斯（301257）：Q3收入增速稳定，毛利率显著回暖